肾移植受者中他汀相关不良事件的发生率
该研究纳入2006至2016年以Medicare为主要支付方的成年单器官肾移植受者57,699例,采用多变量Cox回归分析他汀使用与不良事件的关联。结果显示他汀使用与移植后糖尿病、白内障和横纹肌溶解风险升高相关,与肝损伤风险降低相关,与出血性卒中无显著关联。作者认为他汀总体耐受良好,但可能轻度增加部分不良事件风险。
要点
- 他汀使用与移植后糖尿病风险升高相关(aHR 1.12,95%CI 1.07-1.18)。
- 他汀使用与白内障(aHR 1.22)和横纹肌溶解(aHR 1.37)风险升高相关。
- 他汀使用与肝损伤风险降低相关(aHR 0.82),与出血性卒中无显著关联。
核心结论
- 他汀在肾移植受者中似乎总体耐受良好,但使用可能与非移植后糖尿病、白内障和横纹肌溶解的轻度升高风险相关。
研究设计与样本
- 研究为2006至2016年纳入的成年(18岁或以上)单器官肾移植受者全国性研究,以Medicare为主要支付方,共57,699例。
- 通过处方药索赔确定他汀使用,通过ICD-9/10诊断代码确定他汀相关不良事件。
- 对每个结局采用多变量Cox回归,以他汀使用作为时变暴露。
主要发现
- 移植后糖尿病是最常见结局,5年Kaplan-Meier发生率在他汀使用者中为43%,非使用者中为35%。
- 白内障5年发生率在他汀使用者中为22%,非使用者中为12%;肝损伤为2% vs 3%;出血性卒中为1.9% vs 1.4%;横纹肌溶解为1.5% vs 0.9%。
- 多变量分析中,他汀使用与移植后糖尿病风险升高相关(aHR 1.12,95%CI 1.07-1.18)。
- 他汀使用与白内障(aHR 1.22,95%CI 1.14-1.31)和横纹肌溶解(aHR 1.37,95%CI 1.10-1.71)风险升高相关。
- 他汀使用与肝损伤风险降低相关(aHR 0.82,95%CI 0.71-0.95),与出血性卒中无显著关联(aHR 1.04,95%CI 0.86-1.26)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins are the third most prescribed drug class in kidney transplant recipients as cardiovascular disease is the leading cause of death in this population. However, statins' safety profile remains unclear in kidney transplant recipients who are uniquely burdened by concomitant immunosuppression and comorbidities. We conducted a national study to characterize the association of statin use with adverse events in kidney transplant recipients. METHODS: We studied adult (18 years or older) single-organ kidney transplant recipients in 2006-2016 with Medicare as primary payer ( n =57,699). We used prescription drug claims to capture statin use and International Classification of Diseases 9/10 diagnosis codes to capture statin-related adverse events (post-transplant diabetes mellitus, hemorrhagic stroke, cataract, liver injury, and rhabdomyolysis). We conducted multivariable Cox regression for each outcome with statin use as a time-varying exposure. RESULTS: Post-transplant diabetes mellitus was the most common outcome (5-year Kaplan-Meier incidence; 43% in statin users versus 35% in nonusers), followed by cataract (22% versus 12%), liver injury (2% versus 3%), hemorrhagic stroke (1.9% versus 1.4%), and rhabdomyolysis (1.5% versus 0.9%). In our multivariable analysis, statin use was associated with higher hazard of post-transplant diabetes mellitus (adjust hazard ratio [aHR], 1.12; 95% confidence interval [95% CI], 1.07 to 1.18), cataract (aHR, 1.22; 95% CI, 1.14 to 1.31), and rhabdomyolysis (aHR, 1.37; 95% CI, 1.10 to 1.71) but lower hazard of liver injury (aHR, 0.82; 95% CI, 0.71 to 0.95). Statin use was not associated with hemorrhagic stroke (aHR, 1.04; 95% CI, 0.86 to 1.26). CONCLUSIONS: Statins seem to be generally well tolerated in kidney transplant recipients. However, statin use might be associated with slightly higher risk of post-transplant diabetes mellitus, cataract, and rhabdomyolysis.
引用
- Bae S, Ahn JB, Joseph C, et al. Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2023. PMID: 36800538. doi:10.2215/CJN.0000000000000124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。